Scientific Research News

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that it has entered into a definitive arrangement agreement (the “Arrangement Agreement”) with XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly, “Xeno”), a non-profit biotechnology company, pursuant to which Xeno will acquire (the “Transaction”) all of the issued and outstanding common shares of Repare (the “Com...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an update to the prescribing information for ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for Duchenne muscular dystrophy (DMD). As previously disclosed, the ELEVIDYS label now includes several key updates, including: A boxed warning for the risk of acute serious liver injury (ALI) and acute liver failure (ALF)....

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and being run in collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, nonprofit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL), marking Tempus’ first study collaboration with a non-pr...

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--BUILT Biotechnologies, Inc., an emerging leader in DNA Manufacturing-as-a-Service, today announced that it has been chosen as the preferred manufacturing partner for clients of Neochromosome, Inc. who require large-scale DNA builds. As Neochromosome sunsets its DNA services to focus on its antibody display and cell engineering platforms, the company is offering clients a seamless path to migrate their DNA-construction projects to BUILT's platform. “Neochro...

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies reports Q3 2025 financial results, achieves 86% increase in CyPath® Lung testing revenue....

BOSTON--(BUSINESS WIRE)--Presentations at AMP 2025 show utility of Delve Detect for diagnosing complex CNS infections, such as co-infection and culture-negative presentations...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the fourth quarter and full year fiscal 2025 ended September 30, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal fourth quarter and full year 2025 earnings report and the investor presentatio...

BERLIN--(BUSINESS WIRE)--ESMO AI & Digital Health 2025 - Massive Bio today introduced Reticulum Nexus, the company’s most significant technological leap to date: a patient-centric, multi-agent platform engineered to coordinate the full oncology journey, from first contact to last-mile enrollment, across networks operating at global scale. In an environment where clinical trial access has long been constrained by fragmented data pipelines, site-centric processes, and human-heavy workflows, R...

NEW YORK & BOSTON--(BUSINESS WIRE)--TandemAI closes Series A extension round to accelerate AI-driven drug discovery...

EVANSTON, Ill.--(BUSINESS WIRE)--Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicine, announced today the publication of foundational research demonstrating the power of its proprietary Spherical Nucleic Acid (SNA) platform to create highly potent and targeted cancer therapies. The study, published in the journal ACS Nano by a team led by Flashpoint’s scientific co-founder Professor Chad A. Mirkin at the International Institute for Nanotechnology a...